Jury Awards $2.5 Mln In Roche Accutane Trial
June 1, 2007 06:36

"A New Jersey jury on Tuesday found that Swiss drugmaker Roche Holding AG failed to adequately warn a patient of the bowel disease risks associated with its potent acne medicine Accutane and awarded him $2.5 million in damages. The jury, during its third day of deliberations, also found that the failure to warn was a major contributing cause of his contracting the bowel disease and awarded the plaintiff an additional $119,000 to cover medical expenses. The trial was the first of about 400 U.S. lawsuits involving Accutane, which has been on the market since 1982."

Reuters, New York Times 5/29/07
http://www.nytimes.com/reuters/business/business-roche-accutane.html

- Health Professional Communication
- GlaxoSmithKline Inc.
A New England Journal of Medicine article raised concern about increased risk of heart attack and cardiovascular death in diabetic patients. The conclusions reached require confirmation.

http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2007/index_e.html